YSP Southeast Asia Holding Bhd - ESG Rating & Company Profile powered by AI
This Disclosure score covers 17 UN Sustainable Development Goals including: 'Quality Education', 'Sustainable Cities & Communities' and 'Partnerships for the Goals'. If you are employed by YSP Southeast Asia Holding Bhd and you wish to licence your ESG aseessment, please get in touch. This analysis of YSP Southeast Asia Holding Bhd uses intelligence from across the internet as well as from available filings by YSP Southeast Asia Holding Bhd.
YSP Southeast Asia Holding Bhd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.8; made up of an environmental score of 2.7, social score of 1.6 and governance score of 4.0.
2.8
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1353 | Vera Therapeutics Inc | 2.9 | Medium |
1353 | Veracyte Inc | 2.9 | Medium |
1393 | YSP Southeast Asia Holding Bhd | 2.8 | Medium |
1393 | Bioventix PLC | 2.8 | Medium |
1393 | Bolt Biotherapeutics Inc | 2.8 | Medium |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does YSP Southeast Asia Holding Bhd have an accelerator or VC vehicle to help deliver innovation?
Does YSP Southeast Asia Holding Bhd disclose current and historical energy intensity?
Does YSP Southeast Asia Holding Bhd report the average age of the workforce?
Does YSP Southeast Asia Holding Bhd reference operational or capital allocation in relation to climate change?
Does YSP Southeast Asia Holding Bhd disclose its ethnicity pay gap?
Does YSP Southeast Asia Holding Bhd disclose cybersecurity risks?
Does YSP Southeast Asia Holding Bhd offer flexible work?
Does YSP Southeast Asia Holding Bhd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does YSP Southeast Asia Holding Bhd disclose the number of employees in R&D functions?
Does YSP Southeast Asia Holding Bhd conduct supply chain audits?
Does YSP Southeast Asia Holding Bhd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does YSP Southeast Asia Holding Bhd conduct 360 degree staff reviews?
Does YSP Southeast Asia Holding Bhd disclose the individual responsible for D&I?
Does YSP Southeast Asia Holding Bhd disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does YSP Southeast Asia Holding Bhd disclose current and / or historical scope 2 emissions?
Does YSP Southeast Asia Holding Bhd disclose water use targets?
Does YSP Southeast Asia Holding Bhd have careers partnerships with academic institutions?
Did YSP Southeast Asia Holding Bhd have a product recall in the last two years?
Does YSP Southeast Asia Holding Bhd disclose incidents of discrimination?
Does YSP Southeast Asia Holding Bhd allow for Work Councils/Collective Agreements to be formed?
Has YSP Southeast Asia Holding Bhd issued a profit warning in the past 24 months?
Does YSP Southeast Asia Holding Bhd disclose parental leave metrics?
Does YSP Southeast Asia Holding Bhd disclose climate scenario or pathway analysis?
Does YSP Southeast Asia Holding Bhd disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does YSP Southeast Asia Holding Bhd disclose the pay ratio of women to men?
Does YSP Southeast Asia Holding Bhd support suppliers with sustainability related research and development?
Does YSP Southeast Asia Holding Bhd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does YSP Southeast Asia Holding Bhd reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is YSP Southeast Asia Holding Bhd involved in embryonic stem cell research?
Does YSP Southeast Asia Holding Bhd disclose GHG and Air Emissions intensity?
Does YSP Southeast Asia Holding Bhd disclose its waste policy?
Does YSP Southeast Asia Holding Bhd report according to TCFD requirements?
Does YSP Southeast Asia Holding Bhd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does YSP Southeast Asia Holding Bhd disclose energy use targets?
Does YSP Southeast Asia Holding Bhd disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does YSP Southeast Asia Holding Bhd have a policy relating to cyber security?
Have a different question?
Potential Risks for YSP Southeast Asia Holding Bhd
These potential risks are based on the size, segment and geographies of the company.
Y.S.P. Southeast Asia Holding Berhad, an investment holding company, operates as a pharmaceutical company. It provides prescription products comprising antiasthmatic, antihistamine, and adjuvant therapy products; antibacterial and analgesic lozenges, antibiotics, antidiarrheals, antiemetics, antiprotozoal and antiamoebics, antispasmodics, antispasmodics with psycholeptics, drugs used in BPH, drugs for gout therapy, H2-antagonists, hypnotics and sedatives, antifibrinolytics, nootropics and neurotonics, non-steroidal anti-inflammatory, antipyretics and analgesics, peripheral vasodilators, proton pump inhibitors, skeletal muscle relaxants, anesthesia, anxiolytics, and topical corticosteroids and keratolytics; antidiabetic, antifungal, lipid regulating, antihypertensive, antitussive, antiviral, and ovulation inductive agents; and steroidal, anorectal, topical, and ophthamological preparations. The company also offers non-prescription products, such as anthelmintic agents, antacids, antiinflammatory and digestive enzymes, antipyretics and analgesics, antiplatelet, carminatives, expectorants/mucolytic agents, haemorrhoidal and topical preparations, and laxatives; and traditional medicines. In addition, it provides veterinary pharmaceutical products for aquatic and livestock, including anthelmintics, antibiotics, anticoccidial and drying agent, antifungals, antipyretics and analgesics, disinfectants/antiseptic, electrolytes, enzyme and hormone preparations, hematopoietic nutrients, herbal extracts, vitamins and minerals supplements, antimicrobials, immune?enhancer, larval feeds, and probiotics/water treatment remedy. Further, it offers disposables, medical devices, test kits, medical aids, insect repellents; cosmetics, fine chemicals, and health food products; and management services. It operates in Malaysia, Singapore, the Philippines, Vietnam, Cambodia, Myanmar, Brunei, and other countries. The company was founded in 1987 and is headquartered in Kuala Lumpur, Malaysia.